Biological properties of recombinant α-interferons: 40th Anniversary of the discovery of interferons

Cancer Research

Volumn 58, Issue 12, 1998, Pages 2489-2499

  Pfeffer, Lawrence M ^a   Dinarello, Charles A ^b   Herberman, Ronald B ^c   Williams, Bryan R G ^d   Borden, Ernest C ^e   Bordens, Ronald ^f   Walter, Mark R ^g   Nagabhushan, Tattanahalli L ^f   Trotta, Paul P ^h   Pestka, Sidney ⁱ  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g University of Alabama at Birmingham   (United States)

^h Applied Clin Communications Inc   (United States)

ⁱ RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA2 INTERFERON; ARACHIDONIC ACID; BUSULFAN; CARCINOEMBRYONIC ANTIGEN; CELL SURFACE RECEPTOR; DOXORUBICIN; FIBRONECTIN; FLUOROURACIL; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HYDROXYUREA; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ANTIGENICITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; FEVER; FLU LIKE SYNDROME; HAIRY CELL LEUKEMIA; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BINDING, COMPETITIVE; CYTOKINES; DINOPROSTONE; FORECASTING; HUMANS; INTERFERON TYPE I, RECOMBINANT; NEOPLASMS; PROTEIN CONFORMATION; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 0032526030     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Isaacs, A., and Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. Ser. B., 147: 258-267, 1957.
2. Lindenmann, J. Induction of chick interferon: procedures of the original experiments. Methods Enzymol., 78: 181-188, 1981.
3. Pestka, S. The human interferon-α species and hybrid proteins. Semin. Oncol., 24 (Suppl. 9): S9-4-S9-17, 1997.
4. Zoon, K. C., Bekisz, J., and Miller, D. Human interferon α family: protein structure and function. In: S. Baron, D. H. Coopenhaver, F. Dianzani, W. R. Fleishmann, T. K. Hughes, Jr., G. R. Kimpel, Jr., D. W. Niesel, G. J. Stanton, and S. K. Tyring (eds.), Interferon: Principles and Medical Applications, pp. 95-105. Galveston, TX: The University of Texas Medical Branch at Galveston, 1992.
5. Uzé, G., Lutfalla, G., and Gresser, I. Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell, 60: 225-234, 1990.
6. Domanski, P., Witte, M., Kellum, M., Rubinstein, M., Hackett, R., Pitha, P., and Colamonici, O. R. Cloning and expression of a long form of the β-subunit of the interferon αβ receptor that is required for signaling. J. Biol. Chem., 270: 21606-21611, 1995.
7. Novick, D., Cohen, B., and Rubinstein, M. The human interferon α/β receptor: characterization and molecular cloning. Cell, 77: 391-400, 1994.
8. Lutfalla, G., Holland, S. J., Cinato, E., Monneron, D., Reboul, J., Rogers, N. C., Smith, J. M., Stark, G. R., Gardiner, K., Mogensen, K. E., Kerr, I. M., and Uzé, G. Mutant U5A cells are complemented by an interferon-αβ receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J., 14: 5100-5108, 1995.
9. Domanski, P., and Colamonici, O. R. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev., 7: 143-151, 1996.
10. Nagabhushan, T. L., and Trotta, P. P. Interferons. In: Ullmann's Encyclopedia of Industrial Chemistry, 5th ed., Vol. A14, pp. 365-380. Weinheim, Germany: VCH Verlagsgesellschaft mbH, 1989.
11. Pestka, S., Langer, J. A., Zoon, K. C., and Samuel, C. E. Interferons and their actions. Annu. Rev. Biochem., 56: 727-777, 1987.
12. Sen, G. C., and Lengyel, P. The interferon system: a bird's eye view of its biochemistry. J. Biol. Chem., 267: 5017-5020, 1992.
13. Trotta, P. P., and Siegel, R. J. Interferon: current concepts of mechanisms of action. In: F. M. Muggia (ed.), Concepts, Clinical Developments and Therapeutic Advances in Cancer Chemotherapy, pp. 141-159. Boston: Martinus-Nijhoff, 1987.
14. Nagabhushan, T. L., and Giaquinto, A. Interferon α2b: an overview from a regulatory perspective. In: A. S. Lubiniecki and S. A. Vargo (eds.), Regulatory Practice for Biopharmaceutical Production, pp. 221-234. New York: Wiley-Liss, 1994.
15. Jensen, D. M., Blatt, L. M., Tong, M. J., Lee, W. M., Mullen, K., Joefs, J. C., Keeffe, E., Hollinger, F. B., Heathcote, E. J. L., White, H., Rouse, R. T., Krawitt, E. L., Fromm, H., Black, M., Albert, D., Gerrard, T., and the Consensus Interferon Study Group. Treatment of high viral titer chronic HCV patients with consensus interferon results in a significantly greater number of sustained HCV RNA responders as compared to treatment with interferon α-2b. Presented at the 47th annual meeting of the American Association for the Study of Liver Diseases; November 11, 1996; Chicago, Ill. Abstract 593.
16. Keeffe, E., Blatt, L. M., Dusheiko, G., Tong, M. J., Hollinger, F. B., James, S., Mullen, K., Everson, G., Pimstone, N., Heathcote, E. J. L., Donovan, J., Conrad, A., Schmid, P., Albert, D., Gerrard, T., and the Consensus Interferon Study Group. Differential response to treatment with consensus interferon (CIFN) and IFN α-2b in chronic HCV patients infected with different HCV serotypes. Presented at the 47th annual meeting of the American Association for the Study of Liver Diseases; November 11, 1996; Chicago, Ill. Abstract 594.
17. Pockros, P. J., Tong, M. J., Lee, W. M., van Leeuwen, D. J., Keeffe, E., Bala, K., Killenberg, P. G., Foust, R. T., Rosenblate, H. J., Payne, K. M., Fromm, H., Lesesne, H. R., Black, M., Snyder, R., Gerrard, T., Conrad, A., Blatt, L. M., and the Consensus Interferon Study Group. Relationship between biochemical and virological response to type 1 interferon therapy of chronic HCV infection. Presented at the 47th annual meeting of the American Association for the Study of Liver Diseases; November 9, 1996; Chicago, Ill. Abstract 113.
18. Alton, K. Y., Stabinsky, R., Richards, R., Ferguson, B., Goldstein, L., Altrock, B., Miller, L., and Stebbing, N. Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-γ analogs. In: E. DeMaeyer and H. Schellekens (eds.), The Biology of the Interferon System, pp. 119-128. Amsterdam: Elsevier, 1983.
19. Radhakrishnan, R., Walter, L. J., Hruza, A., Reichert, P., Trotta, P. P., Nagabhushan, T. L., and Walter, M. R. Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography. Structure (Lond.), 4: 1453-1463, 1996.
20. Uzé, G., Lutfalla, G., and Mogensen, K. E. α and β interferons and their receptor and their friends and relatives. J. Interferon Cytokine Res., 15: 3-26, 1995.
21. Cleary, C. M., Donnelly, R. J., Soh, J., Mariano, T. M., and Pestka, S. Knockout and reconstitution of a functional human type I interferon receptor complex. J. Biol. Chem., 269: 18747-18749, 1994.
22. Cook, J. R., Cleary, C. M., Mariano, T. M., Izotova, L., and Pestka, S. Differential responsiveness of a splice variant of the human type I interferon receptor to interferons. J. Biol. Chem., 271: 13448-13453, 1996.
23. Soh, J., Mariano, T. M., Lim, J-K., Izotova, L., Mirochnitchenko, O., Schwartz, B., Langer, J. A., and Pestka, S. Expression of a functional human type I interferon receptor in hamster cells: application of functional yeast artificial chromosome (YAC) screening. J. Biol. Chem., 269: 18102-18110, 1994.
24. Pestka, S. The interferon receptors. Semin. Oncol., 24 (Suppl. 9): S9-18-S9-40, 1997.
25. Müller, U., Steinhoff, U., Reis, L. F., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., and Aguet, M. Functional role of type I and type II interferons in antiviral defense. Science (Washington DC), 264: 1918-1921, 1994.
26. Hwang, S. Y., Hertzog, P. J., Holland, K. A., Sumarsono, S. H., Tymms, M. J., Hamilton, J. A., Whitty, G., Bertoncello, I., and Kola, I. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons α and β and alters macrophage responses. Proc. Natl. Acad. Sci. USA, 92: 11284-11288, 1995.
27. tyk2 tyrosine kinase. Mol. Cell. Biol., 14: 8133-8142, 1994.
28. tyk2, an interferon-α-activated tyrosine kinase, is physically associated with an interferon-α receptor. J. Biol. Chem., 269: 3518-3522, 1994.
29. Yan, H., Krishnan, K., Lim, J. T., Contillo, L. G., and Krolewski, J. J. Molecular characterization of an α-interferon receptor 1 subunit (IFNαR1) domain required for TYK2 binding and signal transduction. Mol. Cell. Biol., 16: 2074-2082, 1996.
30. Kotenko, S. V., Izotova, L. S., Pollack, B. P., Muthukumaran, G., Silvennoinen, O., Paukku, K., Ihle, J. N., and Pestka, S. Jak kinases can substitute for Jak2 in the IFN-γ signal transduction. J. Biol. Chem., 271: 17174-17182, 1996.
31. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Washington DC), 264: 1415-1421, 1994.
32. Fu, X-Y. A direct signaling pathway through tyrosine kinase activation of SH2 domain-containing transcription factors. J. Leukoc. Biol., 57: 529-535, 1995.
33. Constantinescu, S. N., Croze, E., Wang, C., Murti, A., Basu, L., Mullersman, J. E., and Pfeffer, L. M. Role of interferon α/β receptor chain 1 in the structure and transmembrane signaling of the interferon α/β receptor complex. Proc. Natl. Acad. Sci. USA, 91: 9602-9606, 1994.
34. Yang, C. H., Shi, W., Basu, L., Murti, A., Constantinescu, S. N., Blatt, L., Croze, E., Mullersman, J. E., and Pfeffer, L. M. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J. Biol. Chem., 271: 8057-8061, 1996.
35. Faltynek, C. R., Branca, A. A., McCandless, S., and Baglioni, C. Characterization of an interferon receptor on human lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 80: 3269-3273, 1983.
36. Joshi, A. R., Sarkar, F. H., and Gupta, S. L. Interferon receptors: cross linking of human leukocyte interferon α-2 to its receptor on human cells. J. Biol. Chem., 257: 13884-13887, 1982.
37. Vanden Broecke, C., and Pfeffer, L. M. Characterization of interferon-α binding sites on human cell lines. J. Interferon Res., 8: 803-811, 1988.
38. Hertzog, P. J., Hwang, S. Y., Holland, K. A., Tymms, M. J., Iannello, R., and Kila, I. A gene on human chromosome 21 located in the region 21q22.2 to 21q22.3 encodes a factor necessary for signal transduction and antiviral response to type I interferons. J. Biol. Chem., 269: 14088-14093, 1994.
39. Abramovich, C., Chebath, J., and Revel, M. The human interferon α-receptor protein confers differential responses to human interferon-β versus interferon-α subtypes in mouse and hamster cell transfectants. Cytokine, 6: 414-424, 1994.
40. Aguet, A. Molecular-cloning of interferon receptors: a short review. Br. J. Haematol., 79 (Suppl. 1): 6-8, 1991.
41. Langer, J. A., and Pestka, S. Interferon receptors. Immunol. Today, 9: 393-400, 1988.
42. Mogensen, K. E., Uzé, G., and Eid, P. The cellular receptor of the α-β interferons. Experientia (Basel), 45: 500-508, 1989.
43. Pfeffer, L. M., Stebbing, N., and Donner, D. B. Cytoskeletal association of human α-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 84: 3249-3253, 1987.
44. Nanus, D. M., Pfeffer, L. M., Bander, N. H., Bahri, S., and Albino, A. P. Antiproliferative and antitumor effects of α-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res., 50: 4190-4194, 1990.
45. Pfeffer, L. M., and Donner, D. B. The down-regulation of α-interferon receptors in human lymphoblastoid cells: relation to cellular responsiveness to the antiproliferative action of α-interferon. Cancer Res., 50: 2654-2657, 1990.
46. Pfeffer, L. M., and Tamm, I. Comparison of the effects of α and β interferons on the proliferation and volume of human tumor cells (HeLa-S3, Daudi, P3HR-1). J. Interferon Res., 3: 395-408, 1983.
47. Schindler, C., and Darnell, J. E., Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem., 64: 621-651, 1995.
48. Williams, B. R. G. Transcriptional regulation of interferon-stimulated genes. Eur. J. Biochem., 200: 1-11, 1991.
49. Haque, S. J., and Williams, B. R. G. Identification and characterization of an interferon (IFN)-stimulated response element-IFN-stimulated gene factor 3-independent signaling pathway for IFN-α. J. Biol. Chem., 269: 19523-19529, 1994.
50. Sims, S. H., Cha, Y., Romine, M. F., Gao, P-Q., Gottlieb, K., and Deisseroth, A. B. A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter. Mol. Cell. Biol., 13: 690-702, 1993.
51. 2 is required for the formation of interferon-stimulated gene factor 3. EMBO J., 15: 1566-1571, 1996.
52. Hannigan, G. E., and Williams, B. R. G. Signal transduction by interferon-α through arachidonic acid metabolism. Science (Washington DC), 251: 204-207, 1991.
53. Sen, G. C., and Ransohoff, R. M. Interferon-induced antiviral actions and their regulation. Adv. Virus Res., 42: 57-101, 1993.
54. Reich, N. C., Evans, B., Levy, D., Fahey, D., Knight, E., Jr., and Darnell, J. E., Jr. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proc. Natl. Acad. Sci. USA, 84: 6394-6398, 1987.
55. Reid, L., Brasnett, A., Gilbert, C. S., Porter, A. C., Gewert, D. R., Stark, G. R., and Kerr, I. M. A single DNA response element can confer inducibility by both α- and γ-interferons. Proc. Natl. Acad. Sci. USA, 86: 840-844, 1989.
56. Kishimoto, T., Taga, T., and Akira, S. Cytokine signal transduction. Cell, 76: 253-262, 1994.
57. Kalvakolanu, D. V., and Borden, E. C. An overview of the interferon system: signal transduction and mechanisms of action. Cancer Investig., 14: 25-53, 1996.
58. Pfeffer, L. M. Biologic activities of natural and synthetic type I interferons. Semin. Oncol., 24 (Suppl. 9): S9-63-S9-69, 1997.
59. Herberman, R. B. Effect of α-interferons on immune function. Semin. Oncol., 24 (Suppl. 9): S9-78-S9-80, 1997.
60. Ortaldo, J. R., Mantovani, A., Hobbs, D., Rubinstein, M., Pestka, S., and Herberman, R. B. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int. J. Cancer, 31: 285-289, 1983.
61. Ortaldo, J. R., Mason, A., Rehberg, E., Moschera, J., Kelder, B., Pestka, S., and Herberman, R. B. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J. Biol. Chem., 24: 15001-15015, 1983.
62. Ortaldo, J. R., Herberman, R. B., Harvey, C., Osheroff, P., Pan, Y-C. E., Kelder, B., and Pestka, S. A species of human α interferon that lacks the ability to boost human natural killer activity. Proc. Natl. Acad. Sci. USA, 81: 4926-4929, 1984.
63. Li, B-L., Zhao, X-Y., Liu, X-Y., Kim, H. S., Raska, K., Jr., Ortaldo, J., Schwartz, B., and Pestka, S. α-Interferon structure and natural killer cell stimulatory activity. Cancer Res., 50: 5328-5332, 1990.
64. Pestka, S. Interferon from 1981 to 1986. In: S. Pestka (ed.), Methods in Enzymology, Vol. 119, pp. 3-14. New York: Academic Press, 1986.
65. Fellous, M., Nir, U., Wallach, D., Merlin, G., Rubinstein, M., and Revel, M. Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 79: 3082-3086, 1982.
66. Ortaldo, J. R., Pestka, S., Slease, R. B., Rubinstein, M., and Herberman, R. B. Augmentation of human K cell activity with interferon. Scand. J. Immunol., 12: 365-369, 1980.
67. Jewett, A., and Bonavida, B. Interferon-α activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-α secretion by immature human natural killer cells. J. Clin. Immunol., 15: 35-44, 1995.
68. Langer, J. A., Ortaldo, J. R., and Pestka, S. Binding of human α-interferons to natural killer cells. J. Interferon Res., 6: 97-105, 1986.
69. Ozes, O. N., Reiter, Z., and Klein, S. A comparison of interferon-Con1 with natural recombinant interferons-α: antiviral, antiproliferative, and natural killer-inducing activities. J. Interferon Res., 12: 55-59, 1992.
70. Hawkins, M. J., Borden, E. C., Merritt, J. A., Edwards, B. S., Ball, L. A., Grossbard, E., and Simon, K. J. Comparison of the biologic effects of two recombinant human interferons α (rA and rD) in humans. J. Clin. Oncol., 2: 221-226, 1984.
71. Edwards, B. S., Hawkins, M. J., and Borden, E. C. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant α interferons differing in antiviral activity. Cancer Res., 44: 3135-3139, 1984.
72. Dinarello, C. A., Bernheim, H. A., Duff, G. W., Le, H. V., Nagabhushan, T. L., Hamilton, N. C., and Coceani, F. Mechanisms of fever induced by recombinant human interferon. J. Clin. Invest., 74: 906-913, 1984.
73. Dinarello, C. A., and Bernheim, H. A. Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J. Neurochem., 37: 702-708, 1981.
74. Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood, 87: 2095-2147, 1996.
75. Schindler, R., Ghezzi, P., and Dinarello, C. A. Interferons as inhibitors of interleukin 1-induced interleukin 1 synthesis. Lymphokine Res., 8: 275-280, 1989.
76. Ghezzi, P., and Dinarello, C. A. IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-γ. J. Immunol., 140: 4238-4244, 1988.
77. Schindler, R., Ghezzi, P., and Dinarello, C. A. IL-1 induces IL-1, IV. IFN-γ suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J. Immunol., 144: 2216-2222, 1990.
78. Schindler, R., and Dinarello, C. A. A method for removing interleukin-1- and tumor necrosis factor-inducing substances from bacterial cultures by ultrafiltration with polysulfone. J. Immunol. Methods, 116: 159-165, 1989.
79. Schindler, R., and Dinarello, C. A. Ultrafiltration to remove endotoxins and other cytokine-inducing materials from tissue culture media and parenteral fluids. Biotechniques, 8: 408-413, 1990.
80. Dinarello, C. A., Ikejima, T., Warner, S. J., Orencole, S. F., Lonnemann, G., Cannon, J. G., and Libby, P. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol., 139: 1902-1910, 1987.
81. Schindler, R., Clark, B. D., and Dinarello, C. A. Dissociation between interleukin-1β mRNA and protein synthesis in human peripheral blood mononuclear cells. J. Biol. Chem., 265: 10232-10237, 1990.
82. Warner, S. J. C., Auger, K. R., and Libby, P. Interleukin-1 induces interleukin-1. II. Interleukin-1 induces production of interleukin-1 by adult human vascular endothelial cells in vitro. J. Immunol., 139: 1911-1917, 1987.
83. Dinarello, C. A., Lonnemann, G., Maxwell, R., and Shaldon, S. Ultrafiltration to reject human interleukin-1-inducing substances derived from bacterial cultures. J. Clin. Microbiol., 25: 1233-1238, 1987.
84. Ikejima, T., Okusawa, S., Ghezzi, P., van der Meer, J. W. M., and Dinarello, C. A. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J. Infect. Dis., 162: 215-223, 1990.
85. Oliveira, I. C., Mukaida, N., Matsushima, K., and Vilcek, J. Transcriptional inhibition of the interleukin-8 gene by interferon is mediated by the NF-κB site. Mol. Cell. Biol., 14: 5300-5308, 1994.
86. Gribaudo, G., Ravaglia, S., Gaboli, M., Gariglio, M., Cavallo, R., and Landolfo, S. Interferon-α inhibits the murine cytomegalovirus immediate-early gene expression by down-regulating NF-κB activity. Virology, 211: 251-260, 1995.
87. Borden, E. C., and Parkinson, D. A perspective on the clinical effectiveness and tolerance of interferon-α. Semin. Oncol., 25: 3-8, 1998.
88. Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., and Gutterman, J. U. Clinical toxicity of interferon in cancer patients: a review. J. Clin. Oncol., 4: 234-243, 1986.
89. Weiss, K. Safety profile of interferon-α therapy. Semin. Oncol., 25: 9-13, 1998.
90. Plata-Salaman, C. R. Cytokines and anorexia: a brief overview. Semin. Oncol., 25: 64-72, 1998.
91. Dalakas, M. C., Mock, V., and Hawkins, M. J. Fatigue: definitions, mechanisms, and paradigms for study. Semin. Oncol., 25: 48-53, 1998.
92. Jones, T. H., Wadler, S., and Hupart, K. H. Endocrine-mediated mechanisms of fatigue during treatment with interferon-α. Semin. Oncol., 25: 54-63, 1998.
93. Licinio, J., Kling, M. A., and Hauser, P. Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Semin. Oncol., 25: 30-38, 1998.
94. Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., and Hauser, P. Mood and cognitive side effects of interferon-α therapy. Semin. Oncol., 25: 39-47, 1998.
95. Taylor, J. L., and Grossberg, S. E. The effects of interferon-α on the production and action of other cytokines. Semin. Oncol., 25: 23-29, 1998.
96. Antonelli, G. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy. Antiviral Res., 24: 235-244, 1994.
97. Antonelli, G. In vivo development of antibody to interferons: an update to 1996. J. Interferon Cytokine Res., 17 (Suppl. 1): S39-S46, 1997.
98. Vial, T., and Descotes, J. Immune-mediated side effects of cytokines in humans. Toxicology, 105: 31-57, 1995.
99. McKenna, R. M., and Oberg, K. E. Antibodies to interferon-α in treated cancer patients: incidence and significance. J. Interferon Cytokine Res., 17: 141-143, 1997.
100. Meager, A. Natural autoantibodies to interferons. J. Interferon Cytokine Res., 17 (Suppl. 1): S51-S53, 1997.
101. Schellekens, H., Ryff, J. C., and van der Meide, P. H. Assays for antibodies to human interferon-α: the need for standardization. J. Interferon Cytokine Res., 17 (Suppl. 1): S5-S8, 1997.
102. Antonelli, G., Currenti, M., Turriziani, O., and Dianzani, F. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J. Infect. Dis., 163: 882-885, 1991.
103. Antonelli, G., Currenti, M., Turriziani, O., Riva, E., and Dianzani, F. Relative frequency of nonneutralizing antibodies to interferon (IFN) in hepatitis patients treated with different IFN-α preparations. J. Infect. Dis., 165: 593-594, 1992.
104. Camps, J., Garcia-Granero, M., Riezu-Boj, J. I., Larrea, E., de Alava, E., Civeira, M. P., Castilla, A., and Prieto, J. Prediction of sustained remission of chronic hepatitis C after a 12-month course of α-interferon. J. Hepatol. (Amst.), 21: 4-11, 1994.
105. Galton, J. E., Bedford, P., Scott, J. E., Brand, C. M., and Nethersell, A. B. Antibodies to lymphoblastoid interferon. Lancet, ii: 572-573, 1989.
106. Thurmond, L. M., Brand, C. M., Leventhal, B. G., Finter, N. B., and Johnston, J. M. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon. J. Lab. Clin. Med., 118: 232-240, 1991.
107. Berman, E., Heller, G., Kempin, S., Gee, T., Tran, L. L., and Clarkson, B. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon α-2a. Blood, 75: 839-845, 1990.
108. Bonetti, P., Diodati, G., Drago, C., Casarin, C., Scaccabarozzi, S., Realdi, G., Ruol, A., and Alberti, A. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon α-2a. J. Hepatol. (Amst.), 20: 416-420, 1994.
109. Brand, C. M., Leadbeater, L., Bellati, G., Marotta, F., and Ideo, G. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-α subtypes. J. Interferon Res., 13: 121-125, 1993.
110. Douglas, D. D., Rakela, J., Lin, H. J., Hollinger, F. B., Taswell, H. F., Czaja, A. J., Gross, J. B., Anderson, M. L., Parent, K., Fleming, C. R., Canjemi, J. R., O'Brien, P. C., and Powis, P. E. Randomized controlled trial of recombinant α-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig. Dis. Sci., 38: 601-607, 1993.
111. Figlin, R. A., deKernion, J. B., Mukamel, E., Palleroni, A. V., Itri, L. M., and Sarna, G. P. Recombinant interferon α-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J. Clin. Oncol., 6: 1604-1610, 1988.
112. Grander, D., Oberg, K., Lundqvist, M. L., Janson, E. T., Eriksson, B., and Einhorn, S. Interferon-induced enhancement of 2′,5′-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet, 336: 337-340, 1990.
113. Itri, L. M., Campion, M., Dennin, R. A., Palleroni, A. V., Gutterman, J. U., Groopman, J. E., and Trown, P. W. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon α-2a by intra-muscular injection. Cancer (Phila.), 59: 668-674, 1987.
114. Lok, A. S. F., and Lai, C. L. Incidence, neutralizing activity, and clinical significance of interferon antibodies in chronic hepatitis B patients receiving recombinant α-interferons. In: F. B. Hollinger, S. M. Lemon, and H. Margolis (eds.), Viral Hepatitis and Liver Disease, 7th ed., pp. 643-644. Baltimore, MD: Williams & Wilkins, 1991.
115. Lok, A. S. F., Lai, C. L., and Leung, E. K. Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology, 12: 1266-1270, 1990.
116. Milella, M., Antonelli, G., Santantonio, T., Currenti, M., Monno, L., Mariano, N., Angarano, G., Dianzani, F., and Pastore, G. Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C virus infection. Liver, 13: 146-150, 1993.
117. Porres, J. C., Carreno, V., Ruiz, M., Marron, J. A., and Bartolome, J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J. Hepatol. (Amst.), 8: 351-357, 1989.
118. Prummer, O. Interferon-α antibodies in patients with renal cell carcinoma treated with recombinant interferon-α-2a in an adjuvant multicenter trial. The Delta-P Study Group. Cancer (Phila.), 71: 1828-1834, 1993.
119. Quesada, J. R., Rios, A., Swanson, D., Trown, P., and Gutterman, J. U. Antitumor activity of recombinant-derived interferon α in metastatic renal cell carcinoma. J. Clin. Oncol., 3: 1522-1528, 1985.
120. Ronnblom, L. E., Janson, E. T., Perers, A., Oberg, K. E., and Alm, G. V. Characterization of anti-interferon-α antibodies appearing during recombinant interferon-α-2a treatment. Clin. Exp. Immunol., 89: 330-335, 1992.
121. Russo, D., Candoni, A., Zuffa, E., Minisini, R., Silvestri, F., Fanin, R., Zaja, F., Martinelli, G., Tura, S., Botta, G., and Baccarani, M. Neutralizing anti-interferon-α antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (α 2a) and lymphoblastoid interferon-α. Br. J. Haematol., 94: 300-305, 1996.
122. Shtalrid, M., Lugassy, G., Rosensaft, J., and Berrebi, A. Treatment of chronic myeloid leukemia with interferon α (Roferon): results of the Israeli Study Group on CML. Leuk. Lymphoma, 11 (Suppl. 1): 193-197, 1993.
123. Steis, R. G., Smith, J. W., II, Urba, W. J., Clark, J. W., Itri, L. M., Evans, L. M., Schoenberger, C., and Longo, D. L. Resistance to recombinant interferon α-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med., 318: 1409-1413, 1988.
124. von Wussow, P., Pralle, H., Hochkeppel, H-K., Jakschies, D., Sonnen, S., Schmidt, H., Muller-Rosenau, D., Franke, M., Haferlach, T., Zwingers, T., Rapp, U., and Deicher, H. Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukemia. Blood, 78: 38-43, 1991.
125. Bell, J. B., Barfoot, R., Iveson, T., Powles, R. L., and Millar, B. C. Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon α 2b. Br. J. Cancer, 70: 646-651, 1994.
126. Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Jr., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., VanThiel, D. H., Tamburro, C., Lefkowitch, J., Albrecht, J., Meschievitz, C., Ortego, T. J., and Gibas, A., for the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon α. A multicenter randomized, controlled trial. N. Engl. J. Med., 321: 1501-1506, 1989.
127. Dianzani, F., Antonelli, G., Amicucci, P., Cefaro, A., and Pintus, C. Low incidence of neutralizing antibody formation to interferon-α 2b in human recipients. J. Interferon Res., 9 (Suppl. 1): S33-S36, 1989.
128. Golomb, H. M., Ratain, M. J., Fefer, A., Thompson, J., Golde, D. W., Ozer, H., Portlock, C., Silber, R., Rappeport, J., Bonnem, E., Spiegel, R., Tensen, L., Burke, J. S., and Vardiman, J. W. Randomized study of the duration of treatment with interferon α-2b in patients with hairy cell leukemia. J. Natl. Cancer Inst., 80: 369-373, 1988.
129. Jacobs, S. J., Sullivan, L. M., Salfi, M., Grossberg, H., Spiegel, R. J., Leibowitz, P. J., Oden, E. M., Kelsey D. K., and Treuhaft, M. W. Minimal antigenicity of intron A in human recipients demonstrated by three analytical methods. J. Biol. Response Modif., 7: 447-456, 1988.
130. Muller, R., Baumgarten, R., Markus, R., Schultz, M., Wittenberg, H., HintscheKilger, B., Fengler. J-D., von Wussow, P., Meisel, H., Klein, H., Malmus, K., and Schmidt, F. W. Treatment of chronic hepatitis B with interferon α-2b. J. Hepatol. (Amst.), 11 (Suppl. 1): S137-S140, 1990.
131. Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Jr., Lindsay, K., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C., Jacobson, I. M., Sampliner, R., Feit, D., Lefkowitch, J., Kuhns, M., Meschievitz, C., Sanghvi, B., Albrecht, J., and Gibas, A., for the Hepatitis Interventional Therapy Group. A randomized, controlled trial of interferon α-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med., 323: 295-300, 1990.
132. Gisslinger, H., Ludwig, H., Linkesch, W., Chott, A., Fritz, E., and Radaszkiewicz, T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet, i: 634-637, 1989.
133. 2c treatment of cancer patients. Clin. Investig., 70: 136-141, 1992.
134. Hochuli, E. Interferon immunogenicity: technical evaluation of interferon-α2a. J. Interferon Cytokine Res., 17 (Suppl. 1): S15-S21, 1997.
135. Ryff, J. C. Clinical investigation of the immunogenicity of interferon-α2a. J. Interferon Cytokine Res., 17 (Suppl. 1): S29-S33, 1997.
136. Borden, E. C. Interferons. In: J. F. Holland, E. Frei III, J. R. Bast, D. W. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, pp. 1199-1212. Baltimore, MD: Williams & Wilkins, 1997.
137. Gutterman, J. U. Cytokine therapeutics: lessons form interferon α. Proc. Natl. Acad. Sci. USA, 91: 1198-1205, 1994.
138. Golomb, H. M., Jacobs, A., Fefer, A., Ozer, H., Thompson, J., Portlock, C., Ratain, M., Golde, E., Vardiman, J., Burke, J. S., Brady, J., Bonnem, E., and Spiegel, R. α-2 IFN therapy of hairy-cell leukemia: a multicenter study of 64 patients. J. Clin. Oncol., 4: 900-905, 1986.
139. Smalley, R. V., Anderson, S. A., Tuttle, R. L., Connors, J., Thurmond, L. M., Huang, A., Castle, K., Magers, C., and Whisnant, J. K. A randomized comparison of two doses of human lymphoblastoid interferon-α in hairy cell leukemia. Wellcome HCL Study Group. Blood, 78: 3133-3141, 1991.
140. Gresser, I., Maury, C., and Belardelli, F. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases. Int. J. Cancer, 39: 789-792, 1987.
141. Jaffe, H. S., and Herberman, R. B. Rationale for recombinant human interferon-γ adjuvant immunotherapy for cancer. J. Natl. Cancer Inst., 80: 616-618, 1988.
142. Strander, H., Adamson, U., Aparisi, T., Brostrom, L. A., Cantell, K., Einhorn, S., Hall, K., Ingimarsson, S., Nilsonne, U., and Soderberg, G. Adjuvant interferon treatment of human osteosarcoma. Recent Results Cancer Res., 68: 40-44, 1978.
143. Robinson, W. A., Mughal, T. I., Thomas, M. R., Johnson, M., and Spiegel, R. J. Treatment of metastatic malignant melanoma with recombinant interferon α 2. Immunobiology, 172: 275-282, 1986.
144. Kirkwood, J. M. Interferons. Melanoma. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, 2nd ed., pp. 388-411. Philadelphia, PA: J. B. Lippincott Co., 1995.
145. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon α-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial est. 1684. J. Clin. Oncol., 14: 7-17, 1996.
146. Borden, E. C. Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma. Semin. Oncol., 21 (Suppl. 14): 14-22, 1994.
147. Smalley, R. V., Anderson, J. W., Hawkins, M. J., Bhide, V., O'Connell, M. J., Oken, M. M., and Borden, E. C. Interferon α combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N. Engl. J. Med., 327: 1336-1341, 1992.
148. Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., Coiffier, B., and Gisselbrecht, C., for the Groupe d'Etude des Lymphomes de L'Adulte. Recombinant interferon α-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N. Engl. J. Med., 329: 1608-1614, 1993.
149. Bunn, P. A., Jr. Recombinant interferon α-2a, an active agent in advanced cutaneous T-cell lymphomas. Int. J. Cancer, 1 (Suppl.): 9-13, 1987.
150. Wagstaff, J., Scarffe, J. H., and Crowther, D. Interferon in the treatment of multiple myeloma and the non-Hodgkin's lymphomas. Cancer Treat. Rev., 12B: 39-44, 1985.
151. Foon, K. A., Sherwin, S. A., Abrams, P. G., Longo, D. L., Fer, M. F., Stevenson, H. C., Ocho, J. J., Bottino, G. C., Schoenberger, C. S., Zeffren, J., Jaffe, E. S., and Oldham, R. K. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N. Engl. J. Med., 311: 1148-1152, 1984.
152. Alimena, G., Morra, E., Lazzarino, M., Liberati, A. M., Montefusco, E., Inverardi, D., Bernasconi, P., Mancini, M., Donti, E., Grignani, F., Bernasconi, C., Dianzani, F., and Mandelli, F. Interferon α-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood, 72: 642-647, 1988.
153. Kantarjian, H. M., Deisseroth, A., Kurzrock, R., Estrov, Z., and Talpaz, M. Chronic myelogenous leukemia: a concise update. Blood, 82: 691-703, 1993.
154. Ozer, H. Biotherapy of chronic myelogenous leukemia with IFN. Semin. Oncol., 15 (Suppl. 5): 14-20, 1988.
155. Talpaz, M. Use of interferons in the treatment of chronic myelogenous leukemia. Semin. Oncol., 21 (Suppl. 14): 3-7, 1994.
156. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H. J., Pralle, H., Hossfeld, D. K., Queisser, W., Loffler, H., Hochhaus, A., Heinze, B., Georgii, A., Bartram, C. R., Griesshammer, M., Bergmann, L., Essers, U., Falge, C., Queisser, U., Meyer, P., Schmitz, N., Eimermacher, H., Walther, F., Fett, W., Kleeberg, U. R., Kabisch, A., Nerl, C., Zimmermann, R., Meuret, G., Tichelli, A., Kanz, L., Tigges, F. J., Schmid, L., Brockhaus, W., Tobler, A., Reiter, A., Perker, M., Emmerich, B., Verpoort, K., Zankovich, R., Von Wussow, P., Prummer, O., Thiele, J., Buhr, T., Carbonell, F., and Ansari, H. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood, 84: 4064-4077, 1994.
157. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med., 330: 820-825, 1994.
158. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J-L., Maloisel, F., Bouabdallah, R., Guyotat, D., Chron, N., Nicholini, F., Abgrall, J-F., and Tanzer, J. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. For the French Chronic Myeloid Leukemia Study Group. N. Engl. J. Med., 337: 223-229, 1997.
159. Lindner, D. J., Kalvakolanu, D. V., and Borden, E. C. Increasing effectiveness of Interferon-α for malignancies. Semin. Oncol., 24 (Suppl. 9): S9-99-S9-104, 1997.
160. Wadler, S., and Schwartz, E. L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res., 50: 3473-3486, 1990.
161. Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reigh, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res., 58: 808-814, 1998.
162. Sidky, Y. A., and Borden, E. C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res., 47: 5155-5161, 1987.
163. Kattan, M. W., Inoue, Y., Giles, F. J., Talpaz, M., Ozer, H., Guilhot, F., Zuffa, E., Huber, S. L., and Beck, J. R. Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia. Ann. Intern. Med., 125: 541-548, 1996.
164. Cole, B. F., Gelber, R. D., Kirkwood, J. M., Goldhirsch, A., Barylak, E., and Borden, E. Quality-of-life-adjusted survival analysis of interferon α-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol., 14: 2666-2673, 1996.
165. Hillner, B. E., Kirkwood, J. M., Atkins, M. B., Johnson, E. R., and Smith, T. J. Economic analysis of adjuvant interferon α-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J. Clin. Oncol., 15: 2351-2358, 1997.
166. Liberato, N. L., Quaglini, S., and Barosi, G. Cost-effectiveness of interferon α in chronic myelogenous leukemia. J. Clin. Oncol., 15: 2673-2682, 1997.